IL274455A - Caffeic acid derivatives for treating hyperproliferative diseases - Google Patents

Caffeic acid derivatives for treating hyperproliferative diseases

Info

Publication number
IL274455A
IL274455A IL274455A IL27445520A IL274455A IL 274455 A IL274455 A IL 274455A IL 274455 A IL274455 A IL 274455A IL 27445520 A IL27445520 A IL 27445520A IL 274455 A IL274455 A IL 274455A
Authority
IL
Israel
Prior art keywords
acid derivatives
caffeic acid
hyperproliferative diseases
treating hyperproliferative
treating
Prior art date
Application number
IL274455A
Other languages
Hebrew (he)
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/059975 external-priority patent/WO2019094689A1/en
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL274455A publication Critical patent/IL274455A/en

Links

IL274455A 2017-11-10 2020-05-05 Caffeic acid derivatives for treating hyperproliferative diseases IL274455A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762548591P 2017-11-10 2017-11-10
PCT/US2018/059975 WO2019094689A1 (en) 2017-11-10 2018-11-09 Caffeic acid derivatives for treating hyperproliferative diseases

Publications (1)

Publication Number Publication Date
IL274455A true IL274455A (en) 2020-06-30

Family

ID=72846744

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274455A IL274455A (en) 2017-11-10 2020-05-05 Caffeic acid derivatives for treating hyperproliferative diseases

Country Status (1)

Country Link
IL (1) IL274455A (en)

Similar Documents

Publication Publication Date Title
HK1258588A1 (en) Compounds and formulations for treating ophthalmic diseases
HK1257818A1 (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
ZA202001244B (en) Acid treatment for fertilizers to increase zinc solubility and availability
SG11201705093UA (en) Composition for treating il-6-related diseases
IL253945B (en) Kdm1a inhibitors for the treatment of disease
LT3728271T (en) Macrocyclic compounds for treating diseases
HK1212972A1 (en) Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases bet---
HK1252425A1 (en) Triazoles for the treatment of demyelinating diseases
IL278247B (en) Mct4 inhibitors for treating disease
HK1253238A1 (en) Gls1 inhibitors for treating disease
SI3164394T1 (en) Gls1 inhibitors for treating diseases
HK1258994A1 (en) Methods for treatment of diseases
PL3506901T3 (en) Use of kynurenic acid for treating muscle atrophy
HK1257024A1 (en) Aav-epo for treating companion animals
EP3375443A4 (en) Pharmaceutical composition for treating respiratory diseases
EP3383852A4 (en) Compounds for treating proliferative diseases
KR101583452B9 (en) A pharmaceutical composition for treating gastrointestinal diseases
IL274455A (en) Caffeic acid derivatives for treating hyperproliferative diseases
SG11202004230XA (en) Caffeic acid derivatives for treating hyperproliferative diseases
EP3261635A4 (en) Compounds for treating ocular diseases
PL3302463T3 (en) Use of 3-deoxyanthocyanidins for treating ocular diseases
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
EP3354271A4 (en) Agent for treating arthrological diseases
GB201510658D0 (en) Compositions for wound treatment